Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies to Acquire DTC Genetic Test Provider EasyDNA for $4M

NEW YORK — Australian diagnostics firm Genetic Technologies said Monday that it has signed an agreement to acquire EasyDNA, a provider of direct-to-consumer DNA tests, for $4 million in cash and stock.

Under the terms of the deal, Genetic Technologies will pay BelHealth Investment Fund, the majority owner of EasyDNA, $2 million in cash up front. It will pay an additional $1.5 million in Genetic Technologies American Depositary Receipts and $500,000 in cash on the first anniversary of the transaction's closing, which is slated for July 31.

Genetic Technologies will receive all of the websites, brand identities, laboratory testing, and distribution agreements associated with General Genetics Corporation, which trades as EasyDNA.

EasyDNA sells a range of paternity, oncology, animal genomics, and health and wellness genetic tests through 12 agreements with labs in North America, Europe, and the Asia-Pacific region. According to Genetic Technologies, EasyDNA — which is based in Malta and Australia — generated $4.6 million in revenues last year, 20 percent of which was from the UK, and will help accelerate its move into wellness testing.

"With several of our existing tests already CE marked, gaining established sales channels into the EU provides a solid foundation for rapid growth," Genetic Technologies CEO Simon Morriss said in a statement. "Further, with notable recent progress on our Predictive Panel Risk Test, covering six different cancers, having a strong distribution platform in place with global reach will significantly strengthen our rollout strategy as we move this exciting test into commercialization."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.